While nivolumab is a human monoclonal antibody that selectively blocks the PD-1 receptor on the surface of cytotoxic T cells to prevent downregulation of the immune response in malignant tumor cells induced by PD-L1 (Minguet et al., 2016). The gene discussed is CD274; the disease is cancer.